NCT01830140View on ClinicalTrials.gov

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

466

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

May 31, 2014

Conditions
GlaucomaOcular Hypertension
Interventions
DRUG

Bimatoprost 0.01%

Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.

DRUG

Bimatoprost 0.03%

Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.

Trial Locations (2)

Unknown

Artesia

El Paso

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY